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doi:10.1016/j.ejvs.2008.11.035Abstract Aim: During surgery for sapheno-femoral junction (SFJ) and anterior accessory
great saphenous vein (AAGSV) reflux, many surgeons also strip the great saphenous vein
(GSV). This study assesses the short-term efficacy (abolition of reflux on Duplex ultrasound)
of endovenous laser ablation (EVLA) of the AAGSV with preservation of a competent GSV in
the treatment of varicose veins occurring due to isolated AAGSV incompetence.
Method: Thirty-three patients (21 women and 12 men) undergoing AAGSV EVLA alone (group A)
and 33 age/sex-matched controls undergoing GSV EVLA (Group B) were studied. Comparisons
included ultrasound assessment of SFJ competence, successful axial vein ablation, Aberdeen
Varicose Vein Symptom Severity Scores (AVVSS) and a visual analogue patient-satisfaction
scale.
Results: At the 1-year follow-up, EVLA had successfully abolished the target vein reflux
(AAGSV: median length 19 cm (inter-quartile range, IQR: 14e24 cm) vs. GSV: 32 cm (IQR 24e
42 cm)) and had restored SFJ competence in all patients. Twenty of the 33 patients (61%) in
group A and 14 of the 33 (42%) in group B (pZ 0.218) required post-ablation sclerotherapy
at 6 weeks post-procedure for residual varicosities. The AVVSS at 12 months follow-up had
improved from the pre-treatment scores in both the groups (group A: median score 4.1 (IQR
2.1e5.2) vs. 11.6 (IQR: 6.9e15.1) p< 0.001; group B: median score 3.3 (IQR 1.1e4.5) vs.
14.5 (IQR 7.6e20.2), p< 0.001), with no significant difference between the groups. Patient-
satisfaction scores were similar (group A: 84% and group B: 90%).
Previous intervention in group A included GSV EVLA (nZ 3) or stripping (nZ 9). Thus, the
GSV was preserved in 21 patients. The AVVSS also improved in this subgroup (4.4 (2.0e5.4)
vs. 11.4 (6.0e14.1), p< 0.001) and SFJ/GSV competence was found to be restored at the 1-
year follow-up.
Conclusions: AAGSV EVLA abolishes SFJ reflux, improves symptom scores and is, therefore,3 3922823; fax: þ44 113 3922624.
edsth.nhs.uk (M.J. Gough).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
478 N.S. Theivacumar et al.Table 1 Patient demography an
Group A (AAGSV reflux) and Group
Number of patients (limbs)
Age
Male:female
Primary:recurrent varicose veins
CEAP classification
C2
C3
C4
C5/6
All patients:
Ep As Prsuitable for treating varicose veins associated with AAGSV reflux.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Incompetence at the sapheno-femoral junction (SFJ) is the
most common cause (70%)1,2 of varicose veins, and SFJ
ligation and stripping of the great saphenous vein (GSV) are
the standard treatment for varicose veins due to GSV
reflux. In some patients, reflux may occur in the anterior
accessory great saphenous vein (AAGSV) rather than the
GSV, although many surgeons strip the latter when per-
forming surgery. Endovenous laser ablation (EVLA) employs
laser energy to ablate incompetent axial veins selectively
and was originally described for the treatment of GSV reflux
and its related varicosities.3 This study assesses the safety
and short-term efficacy of AAGSV EVLA with preservation of
a competent GSV in patients with isolated SFJ/AAGSV
reflux.
Methods
Patients
Of the 474 patients who had laser treatment for their
varicose veins between March 2004 and January 2007 at the
Leeds Vascular Institute, 33 patients (median age: 43
(range: 32e65) years; 21 women and 12 men) underwent
AAGSV EVLA alone (group A) for isolated SFJ/AAGSV reflux.
Twelve of these patients had undergone previous treatment
for varicose veins (GSV EVLA (nZ 3) and surgical stripping
of GSV (nZ 9)). Outcomes in these patients were compared
with those for 33 age/sex-matched controls who had
undergone GSV EVLA alone during the same time period
(Group B: isolated SFJ/GSV reflux), 13 of whom had
previous treatment for varicose veins. Demographic data
and the disease severity (Clinical, Etiology, Anatomy and
Pathophysiology (CEAP) classification)4 for the two groups
are compared in Table 1. Patients who had varicosities
(primary or recurrent) arising from an incompetent SFJ with
reflux in either the AAGSV (Group A) or GSV (group B) were
included. Patients who had previous deep vein thrombosis
(DVT) and those who had reflux in more than one axial veind CEAP classification for
B (GSV reflux).
Group A Group B
33 (33) 33 (33)
43 (32e65) 43 (32e65)
21:12 21:12
21:12 20:13
28 (85%) 26 (79%)
4 (12%) 5 (15%)
1 (3%) 1 (3%)
0 1 (3%)(AAGSV and GSV) were excluded from this study. Further,
limbs that had intra-saphenous reflux with a competent SFJ
were also excluded.
Data collection and follow-up
Prior to EVLA, all patients underwent a duplex ultrasound
scan (DUS; TITAN, Sonosite Inc., Bothell, USA, 5e10 MHz
linear probe) to determine the site of superficial venous
incompetence. Previous treatment for varicose veins was
documented. Ultrasound examination was performed on
the patient in a standing position. Following calf compres-
sion and release, retrograde flow in the axial vein lasting
>1 s represented significant reflux. The diameter of the
GSV (5e10 cm distal to the SFJ whilst standing) was
measured in both groups, as well as the AAGSV diameter in
group A. Suitability for GSV EVLA was established using
criteria described previously.5 Similarly, suitability for
AAGSV EVLA depended upon a 10-cm long, relatively
straight, segment of AAGSV immediately distal to the SFJ,
an absence of significant varicosities arising within 10 cm of
the SFJ and an AAGSV diameter of 3 mm at the intended
cannulation site (Fig. 1). Further, the common anatomical
variations in AAGSV anatomy, together with an indication as
to whether EVLA is appropriate, are shown in Fig. 2. Disease
severity was assessed using ‘C’ of the CEAP clinical classi-
fication4 prior to treatment (following DUS examination, all
patients were found to be Ep As Pr) and the Aberdeen
Varicose Vein Severity Score (AVVSS) was determined
before and at 1 year after EVLA. All data were collected
prospectively by a consultant vascular surgeon or vascular
research fellow.
EVLA was performed using tumescent local anaesthesia
(0.1% lignocaine) and an 810-nm diode pulsed laser at 12 W
power delivering 60e80 J cm1. Neither concomitant phle-
bectomies nor foam sclerotherapy was undertaken.
Following treatment, a compression bandage was applied
for a week, followed by class II support stocking for another
week. Patients were reviewed at 6, 12 and 52 weeks. All
patients with visible residual varicosities of 4-mm diameter
or greater were treated with foam sclerotherapy at 6 weeks
(if required) using 0.5e1% sodium tetradecyl sulphate (STD)
foam (Fibro-vein, STD Pharmaceutical Products Ltd.,
Hereford, England) that was prepared by the Tessari
method.6 A non-stretch compression bandage was applied
for 1 week following foam sclerotherapy of residual
varicosities.
During follow-up, in addition to clinical examination for
residual varicosities, symptomatic improvement and
complications, DUS was performed at 6, 12 and 52 weeks to
assess SFJ and tributary competence and ablation of the
treated axial vein. Patency of the deep veins was assessed
at 6 and 12 weeks, and the diameters of visible veins were
re-measured at 1 year. Absence of flow in a non-
compressible vein or a non-visible axial (GSV or AAGSV) vein
on DUS represented successful ablation. The primary
Incompetent 
AAGSV≥10cm
Diameter≥3mm
Competent
/absent GSV 
FV
SFJ
Figure 1 EVLA suitability of AAGSV in Group A patients.
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ment in AVVSS in both groups at 1 year post-procedure.
Patient satisfaction was assessed at the 1-year follow-up
using a visual analogue scale with scores from 1 to 10 on
a 10-cm scale. Patients were asked to locate their satis-
faction point on this scale which was then calculated as
a percentage. A log of complications was maintained
throughout the study. Secondary outcomes included
patients’ satisfaction, sclerotherapy requirement and
complication rates. All data were collected prospectively.
Statistical analysis
The AVVSS before and after laser ablation were compared
within a group using a Wilcoxon test, and the improvements
in AVVSS between groups were compared by a Manne≥10cm≥10cm
AAGSV
GSV GSV
AAGSV
 Suitable  Suitable
Figure 2 Laser suitability of differentWhitney U test. Sclerotherapy requirements were
compared using a chi-square (c2) test. A p-value of <0.05
was considered significant. Data descriptors are the median
(inter-quartile range, IQR), unless stated otherwise. All
analyses were performed using the statistical package
SPSS for Windows (SPSS ver. 14.0, Chicago, IL, USA).
Results
The treatment details for both groups are summarised in
Table 2. All treated AAGSVs and GSVs were completely
ablated, and SFJ reflux was found to be abolished in all
patients of both groups at the 1-year follow-up. Foam
sclerotherapy for residual varicosities was required in 20 of
the 33 patients (61%) in group A and 14 of the 33 patients
(42%) in group B (c2Z 2.2 (dfZ 1) pZ 0.218). Median
patient-satisfaction scores were similar (group A: 84% and
group B: 90%, pZ 0.23) and the AVVSS had improved at 1
year when compared to pre-treatment scores (group A:
median 4.1 (IQR: 2.1e5.2) vs. 11.6 (IQR: 6.9e15.1) and
group B: 3.3 (IQR: 1.1e4.5) vs. 14.5 (IQR: 7.6e20.2);
p< 0.001 for both groups). The percentage improvement in
AVVSS was 64.6% (group A) and 77.2% (group B), with no
significant difference between the groups (pZ 0.18,
ManneWhitney test).
None of the participants developed a DVT or signs of
sensory nerve damage, although two patients in group A
and one in group B had symptoms of phlebitis in the EVLA-
treated vein before sclerotherapy was performed. In addi-
tion, of the 34 patients (from both groups) who received
delayed foam sclerotherapy, five (three in group A and two
in group B) developed symptomatic phlebitis. Although skin
staining was not documented at 6 weeks, it was present in
11 patients following foam sclerotherapy at 12 weeks. This
had faded in all patients by the 1-year follow-up, but was
still visible in three of the 34 (9%) patients. No other
complications occurred.
Twelve patients in group A had undergone previous
treatment for varicose veins, and thus the GSV was only
preserved in the remaining 21 patients. These were all in
continuity with the SFJ without evidence of reflux at the
1-year follow-up, with no change in mean GSV diameter (3.2GSVGSV
AAGSV AAGSV
≥10cm
 Suitable (GSV)Unsuitable
anatomical patterns of AAGSV reflux.
Table 2 Details of the vein for EVLA in Group A (AAGSV
reflux) and Group B (GSV reflux).
Parameters Group A
(AAGSV)
Group B
(GSV)
p-value
Diameter of
vein (mm)
7.1 (5.2e8.0) 7.8 (5.2e8.8) 0.12
Length of
vein (cm)
19 (14e24) 32 (24e42) <0.001
Total laser
energy (J)
1178
(912e1488)
2012
(1460e2466)
<0.001
Laser energy
density (J cm1)
61 63 0.34
All data are shown as median (inter-quartile range).
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The AVVSS scores also improved in this subgroup (median
4.4 (IQR 2.0e5.4) vs. 11.4 (IQR 6.0e14.1), pZ 002). The
treated AAGSV was not visible on DUS at the 1-year follow-
up in any patient in group A, and no clinical recurrences
were visible in patients from either group at final review.
Discussion
Abolition of SFJ reflux requires ablation of all incompetent
axial veins arising from the junction. Thus, AAGSV ablation
abolishes reflux at the SFJ when associated with isolated
reflux in this vein. Fig. 3 illustrates the fate of the SFJ, GSV
and AAGSV following successful AAGSV ablation. The
subsequent improvement in symptom scores was similar to
that achieved after GSV ablation.
Although SFJ reflux can be associated with incompe-
tence in one or more of its tributaries, most patients (85%)
only have GSV reflux,7 and GSV ablation abolishes SFJ reflux
with persistent competence of its tributaries at the 1-year
follow-up.8 Equally, when SFJ incompetence is associated
with reflux in more than one axial vein (5%),7 all incompe-
tent veins require either ablation (EVLA) or stripping
(surgery) to restore SFJ competency.Pre-EVLA (Incompetent SFJ)
Incompetent
AAGSV
Competent GSV
FV
 SFJ
Figure 3 Diagrammatic representationIsolated AAGSV/SFJ reflux occurs in around 10% of the
patients.7 During conventional surgery, many surgeons also
strip the competent GSV because of the possibility that,
post-SFJ ligation, neo-vascularisation may subsequently
promote GSV reflux and recurrence. Although stripping of
incompetent axial veins is required to avoid recurrence,
there is no evidence to support this for competent veins.
During EVLA, selective ablation of the incompetent axial
vein can be achieved without the temptation to ablate
competent axial veins. Thus, a healthy GSV may be
preserved. Subsequently, it will still be available, if
required, for vascular or coronary artery reconstruction.
Ideally, AAGSV EVLA should have been compared with
surgery for AAGSV reflux. The issue of routine practice for
this type of reflux (in the UK) made this comparison diffi-
cult. Further, most patients with varicose veins now choose
EVLA over surgery if their axial veins are suitable for
ablation. Nevertheless, the comparison of AAGSV and GSV
EVLA in this study suggests that symptom improvement is
similar for both procedures. Further, previous studies show
that EVLA and surgery in patients with SFJ/GSV reflux 9,10
are equally effective in improving symptom scores.
Despite these results, EVLA is unlikely to replace
surgery for all patients with SFJ/AAGSV reflux as
anatomical considerations indicate that it is only feasible
in 70% of cases (Fig. 2) (unpublished data). Although not
statistically significant (because of the small sample size),
the sclerotherapy requirement was higher following AAGSV
EVLA as compared to after GSV EVLA. This reflects the
shorter segment of AAGSV that can be ablated, and the
extensive varicosities that may be present distal to the
site of vein cannulation. This is consistent with previous
findings that the need for adjuvant sclerotherapy is mini-
mised by commencing ablation at the lowest point of
reflux.11
Following GSV EVLA, almost 40% of the patients do not
have any tributaries in continuity with the SFJ.7 In contrast,
following AAGSV EVLA, the GSV remains in continuity with
the SFJ in all patients, allowing normal GSV function.Post-EVLA (competent SFJ at 1-year)
FV
 SFJ
Ablated
AAGSV 
Still competent
GSV at 1-year 
of GSV-sparing AAGSV laser ablation.
EVLA for Anterior Accessory Great Saphenous Vein Reflux 481In conclusion, GSV-sparing EVLA of the AAGSV abolishes
SFJ reflux associated with isolated SFJ/AAGSV reflux and
improves symptom scores to a similar degree as GSV EVLA
with no evidence of GSV neo-reflux or recurrent varicosities
at the 1-year follow-up. This treatment option preserves
the healthy GSV for future use if required. Although long-
term follow-up is required, the technique appears both safe
and effective.
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